Prescription confusion may have contributed to woman's death
Photo:
David GABIS / 123RF
A coroner says Health New Zealand should centralise medicine dispensing records after he found a mistake with a morphine prescription may have contributed to a Levin woman's death.
Coroner Mark Wilton found 71-year-old Norma Collins' death, at her home in May 2022, was associated with chronic obstructive pulmonary disease (COPD), with a background of excessive morphine administration.
He could not determine the exact cause of Collins' death because she was cremated before it was reported to the coroner, and no post-mortem or toxicological analysis was done.
But he found a GP at Ōtaki Medical Centre inadvertently prescribed a higher strength and dosage for Collins, which the pharmacist did not know about - and could not alert crucial people to.
Collins suffered from end stage COPD with type 2 respiratory failure, pulmonary hypertension and anxiety.
In the lead-up to her death she was prescribed morphine at 1mg strength at a dose of 2.5 to 5ml every three hours as needed by doctors at the Arohanui Hospice.
Her daughter, who was Collins' carer, administered the morphine. She was advised to contact Ōtaki Medical Centre for repeat prescriptions. She did this in late May, concerned the liquid morphine was running out.
A GP at the practice - who was not Collins' usual doctor, nor the lead practitioner at the centre - prescribed a higher dosage of 50ml of liquid morphine, at a higher strength of 10mg, administered at 1mg amounts.
The GP told the Health and Disability Commissioner he checked prescribing records and the Ministry of Health database for Collins' medication history, but could find no previous prescription for liquid morphine, only one for a slow-release 10mg morphine tablet.
He said he had not had specific palliative care training.
"He said that he was unaware that Collins had previously been prescribed liquid morphine of a different dose and concentration by a doctor at Arohanui Hospice," Wiltobn said.
The prescription was sent to Berrys Tararua Pharmacy, which had not dispensed the first prescription for Collins. It did not have access to her dispensing records so did not advise her daughter of any change.
Wilton's report found Collins' daughter administered the drug as she had been doing - noticing her mother was drowsy and sleeping for hours at a time.
"Collins' daughter did not think this was unusual as her mother had slept for long periods of time previously."
She was found dead in her bed the morning of 31 May.
Wilton said Health NZ should centralise dispensing records and share dispensing information through the New Zealand Electronic Prescription Service, following a previous finding by Coroner Alexandra Cunninghame.
The service allows communication between prescribers and pharmacists, including emailing prescriptions and notifications for medications that have not been dispensed.
He said if Berrys Tararua Pharmacy had access to dispensing records, the pharmacist could have checked out the different prescription.
"This would have allowed the pharmacist at [Berrys Tararua Pharmacy] the opportunity to alert Collins' daughter to the difference in strength and dosage, or to question the GP at [Ōtaki Medical Centre] about the difference."
Health NZ told Wilton it was making progress towards centralising dispensing records, but ultimately depended on funding allocation.
Wilton said the Health and Disability Commissioner made recommendations to both the Ōtaki Medical Centre and Berrys Tarurua Pharmacy for future changes, and that the commissioner was satisfied this had been met.
Sign up for Ngā Pitopito Kōrero, a daily newsletter
curated by our editors and delivered straight to your inbox every weekday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RNZ News
2 hours ago
- RNZ News
Single MRI scan could be used to estimate dementia risk
The new tool was tested out on 50,000 brain scans. Photo: Stock New Zealand scientists have helped develop an internationally groundbreaking tool that estimates a person's risk of getting dementia and other age-related diseases. It uses a single MRI scan that can be done in mid-life and before someone is showing any signs of the conditions. Otago University scientists worked with Duke and Harvard universities in the United States and have published their findings in the prestigious medical journal Nature Aging this week. Data from Otago's Dunedin Study - which has followed 1037 participants since they were born in 1972 and 1973 - has been critical in the work. That study looked at changes in blood pressure, glucose and cholesterol levels, tooth and gum health and other body functions over 20 years to see how quickly people were ageing. That data was then compared with an MRI taken when the study participants were 45 and a tool - an algorithm known as Dunedin PACNI - was developed that can look at anyone's MRI and estimate how they might age. Dunedin Study director Professor Moana Theodore said study members who had higher or faster PACNI scores were more likely to have poorer health. "And also poorer physical functioning, things like walking and balance, and also poorer cognitive function, things like poorer memory even though they were, at that stage in their mid 40s," she said. The new tool was then tested out on 50,000 brain scans from data on people aged 50-89 in other parts of the world. "In those studies of older people we were able to identify things like the development of chronic disease, so, an increased likelihood of heart attacks or strokes, an increased risk of being diagnosed with dementia over time and even an increased mortality," she said. The study found those who were ageing faster had more shrinkage in the hippocampus region of the brain and performed worse on cognitive tests. Professor Theodore said the tool could help change outcomes for people. "If we can predict ageing, especially in mid-life.... then what we are able to do is prevent, possibly intervene earlier on to stop or slow down age related diseases like dementia for which there is currently no clear treatment," she said She and her team were incredibly proud of the work - and she thanked the Dunedin Study members and their families for their 50 year contribution. "It's wonderful to have a New Zealand study that is at the forefront of international research on ageing and how to support people to age positively and well and how to reduce age related diseases that cause people to have poorer quality of life later in life," she said. DunedinPACNI will be freely available for scientists around the world to use to further their own work on ageing. Sign up for Ngā Pitopito Kōrero , a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
RNZ News
14 hours ago
- RNZ News
More than meds: Why easier access to ADHD treatment has to be part of a whole-system approach
By Belinda Wheaton, Byron Rangiwai, Nicholas Bowden, and Stephanie D'Souza* of Photo: AFP / Thom Leach / Science Photo Library Analysis - New Zealanders with attention-deficit hyperactivity disorder (ADHD) will now have easier access to diagnosis and medication after the government changed prescribing rules . But there is still so much we don't know about ADHD in Aotearoa. And while these changes will help many, easier access to medication alone won't fill the gaps in other supports people with ADHD need to live well. From February 2026, trained GPs and nurse practitioners will be able to diagnose and treat ADHD. Under the current system, only paediatricians or psychiatrists can make the diagnosis. GPs and nurse practitioners then provide follow-up care. The current process, which is both time-consuming and expensive , has been widely criticised . The government's changes are expected to at least partially address these issues. One major barrier to progress is the general lack of knowledge about adult ADHD. The condition is broadly understood as causing persistent patterns of inattention, hyperactivity and impulsivity. In adults, ADHD can have a profound impact on family and work situations, substance abuse and a wide range of psychiatric disorders. But it has largely been ignored in older age groups, with some believing people "grow out" of the condition . People with ADHD also often possess strengths, including creativity, spontaneity, high energy, risk tolerance and an ability to think divergently. Many also demonstrate strong problem-solving skills under pressure, passion-driven focus and persistence when engaged in meaningful tasks. Worldwide estimates suggest ADHD in adults ranges from 2.5 percent to 3.4 percent of most populations. But England's 2023 Adult Psychiatric Morbidity Survey found 13.9 percent of adults met criteria warranting clinical assessment. Only 0.5 percent had been professionally diagnosed. In New Zealand, estimates rely on indirect measures such as medication dispensing rates. Recent research found 0.6 percent of the adult population in New Zealand was receiving drug treatment for ADHD. Based on a conservative estimate of 2.6 percent of adults with ADHD, this shows a large " treatment gap " exists. Drug dispensing data in New Zealand also shows gaps in who gets diagnosed with ADHD. Māori and Pacific peoples are less likely to receive ADHD medications . These inequities begin early. Tamariki Māori screened for ADHD at age four are less likely to receive medication than their non-Māori peers. There are also substantial differences in the age of diagnosis across sociodemographic groups. These inequities raise serious concerns about access and systemic bias. International research shows that untreated ADHD is linked to worse mental and physical health, higher mortality, and reduced life expectancy. ADHD prevalence is also five times higher among youth prisoners and ten times higher among adult prisoners compared to the general population. In Australia, ADHD's social and economic costs are estimated at AU$20.42 billion per year, or $25,071 per person. Our ongoing research, including a survey, looks at the lived experiences of adults with diagnosed or suspected ADHD in New Zealand. Many have described the healthcare system as "broken". Survey respondents reported long wait times, high costs for diagnosis and treatment and a lack of expertise amongst health professionals. They also described ongoing stigma and misunderstanding about the lived reality of ADHD. The survey mirrors international research showing how longstanding myths and stigmas about what ADHD is and who it affects have impeded societal understanding. Adult women were overrepresented in the sample, constituting 83 percent of the 689 participants, with over 80 percent reporting being diagnosed after age 24, reflecting global trends of underdiagnosis in early age among women. Research suggests ADHD in women is often missed or misdiagnosed , partly due to outdated knowledge and lack of understanding about its presentation in women, compounded by high rates of coexisting conditions such as anxiety, depression, substance use and autism. Growing evidence shows many of the negative outcomes of ADHD are mitigated by treatment with medication. One study from Sweden found a significant association between initiating ADHD medication treatment and lower mortality. However, medication is only part of the solution . Strategies focused on the strengths of people with ADHD can have huge benefits for the individual, their whānau and communities. Particularly when they receive timely diagnosis, treatment and necessary accommodations. Researchers argue that while ADHD medications provide effective treatment, they should never be the only form of treatment offered. Expanding prescribing authority is a vital step, but this alone will do little to increase access to psychological and allied health supports to ensure the right care can be provided to people with ADHD. There continues to be an urgent need to address gaps in data and understanding, to provide an evidence-based assessment of the areas where research, funding and policy initiatives need to be targeted. Trends show that some groups, including Māori and women, are disproportionately affected by a lack of knowledge and services. As the government revises how ADHD is diagnosed and treated, it must address these discrepancies. There is also a complex but poorly understood relationship between ADHD and other neurodevelopmental conditions, such as autism, that needs further investigation. As ADHD New Zealand chairperson Darrin Bull has argued , a "whole-of-system" approach is required to support those with ADHD in New Zealand. This story was first published on The Conversation .
RNZ News
15 hours ago
- RNZ News
Mosquitos could become a tool for disease control
Pesky blood sucking mosquitoes could turn into power houses of disease control. Auckland University researchers have a million dollars in government funding to investigate whether the insects can be used as a bio security tool by collecting and checking their blood to track disease outbreaks. Professor Jacqueline Beggs from the University of Auckland's Faculty of Science is leading the project and spoke to Lisa Owen. Tags: To embed this content on your own webpage, cut and paste the following: See terms of use.
